Published on November 3, 2009 at 7:10 AM
Research and Markets (http://www.researchandmarkets.com/research/6539e0/russia_pharmaceuti) has announced the addition of the "Russia Pharmaceuticals and Healthcare Report Q4 2009" report to their offering.
The Russia Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Russia's pharmaceuticals and healthcare industry.
This quarter BMI introduces 10-year forecasts for the Russian pharmaceutical markets, providing an opportunity to look beyond the current financial crisis and assess the growth potential for the largest and most populous pharmaceutical market in Central and Eastern European (CEE). By 2018, we forecast that the Russian pharmaceutical market will be worth US$50.9bn, representing an 11.28% compound annual growth rate (CAGR) - making Russia one of the most attractive markets over the long term. For the 2008 to 2013 period, growth in US dollar terms is forecast at a CAGR of 13.30%, reaching US$31.6bn in 2013, an impressive figure given our current forecast that the market will contract in US dollar value by 9.1% this year.
Key Topics Covered:
EXECUTIVE SUMMARY
SWOT ANALYSIS
PHARMACEUTICAL BUSINESS ENVIRONMENT RATINGS
RUSSIA - MARKET SUMMARY
REGULATORY REGIME
INDUSTRY DEVELOPMENTS
INDUSTRY FORECAST SCENARIO
COMPETITIVE LANDSCAPE
COMPANY PROFILES
COUNTRY SNAPSHOT: RUSSIA DEMOGRAPHIC DATA
BMI METHODOLOGY
Companies Mentioned:
- Berlin-Chemie/Menarini Pharma GmbH
- Gedeon Richter
- Krka
- Lek ovartis/Sandoz)
- Stada AG (Stada CIS)
- Verofarm
http://www.researchandmarkets.com